Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply
Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply
Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia.
Find out what a historical investment in SENTI BIOSCIENCES HOLDINGS I would be worth today using our SNTI stock calculator.
Market Capitalisation
$27.42M
Price-earnings ratio
-
Dividend yield
0.00%
Volume
178.79K
High today
$0.98
Low today
$0.86
Open price
$0.89
52-week high
$3.88
52-week low
$0.77
Ready to start your investing journey with Stake?
Open an accountThis is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in SNTI on Stake
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
SNTI related stocks